Illumina Exec: More Than 200 GAs Sold In ‘07; Paired Ends Still in Early Access | GenomeWeb
Following a year defined by strong sales of its Genome Analyzer sequencer, Illumina kicked off 2008 with a major restructuring.
 
In the first year that Illumina sold the GA, it shipped more than 200 units, CEO Jay Flatley told investors at a conference this week. He also talked about ways in which the company wants to improve the platform, such as enabling paired-end sequencing.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.